These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 14996694
1. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C. Ann Intern Med; 2004 Mar 02; 140(5):I67. PubMed ID: 14996694 [No Abstract] [Full Text] [Related]
2. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Ann Intern Med; 2004 Mar 02; 140(5):346-55. PubMed ID: 14996676 [Abstract] [Full Text] [Related]
3. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases]. Lopukhova NL. Eksp Klin Gastroenterol; 2007 Mar 02; (4):146-52. PubMed ID: 18409502 [No Abstract] [Full Text] [Related]
4. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation. DeNardo Z, Choi M, Stiller M, Buechel D. Kaohsiung J Med Sci; 2017 Nov 02; 33(11):584-585. PubMed ID: 29050677 [No Abstract] [Full Text] [Related]
5. Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b. Ann Intern Med; 2009 Apr 21; 150(8):I-34. PubMed ID: 19380849 [No Abstract] [Full Text] [Related]
6. Side effects of therapy for chronic hepatitis C. Russo MW, Fried MW. Gastroenterology; 2003 May 21; 124(6):1711-9. PubMed ID: 12761728 [No Abstract] [Full Text] [Related]
7. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis]. Klinker H. MMW Fortschr Med; 2003 Oct 09; 145(41):39-40. PubMed ID: 14655480 [No Abstract] [Full Text] [Related]
8. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X, Freshwater D, Ryder S, Mills PR, Alexander GJ, Forton D, Foster GR. J Hepatol; 2014 Apr 09; 60(4):699-705. PubMed ID: 24291239 [Abstract] [Full Text] [Related]
9. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis. Ann Intern Med; 2013 Dec 03; 159(11):I-14. PubMed ID: 24297207 [No Abstract] [Full Text] [Related]
10. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Dig Dis Sci; 2009 Jun 03; 54(6):1369-72. PubMed ID: 18770036 [No Abstract] [Full Text] [Related]
11. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C]. Abellán Galiana P, Pérez-Lázaro A, Aguilera Sancho-Tello V, Merino Torres JF, Berenguer Haym M, Piñón Sellés F. Endocrinol Nutr; 2009 Mar 03; 56(3):136-9. PubMed ID: 19627727 [Abstract] [Full Text] [Related]
12. Short-duration therapy for hepatitis C: suitable for all? Mangia A. J Viral Hepat; 2007 Apr 03; 14(4):221-7. PubMed ID: 17381713 [Abstract] [Full Text] [Related]
13. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Sagir A, Wettstein M, Heintges T, Häussinger D. Dig Dis Sci; 2002 Mar 03; 47(3):562-3. PubMed ID: 11911342 [No Abstract] [Full Text] [Related]
14. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C]. Zhdanov KV, Gusev DA, Kozlov KV, Shishkin MK, Sukachev VS, Shakhmanov DM, Zhabrov SS. Voen Med Zh; 2015 Apr 03; 336(4):44-9. PubMed ID: 26454938 [Abstract] [Full Text] [Related]
15. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W. Eur J Gastroenterol Hepatol; 2013 May 03; 25(5):601-5. PubMed ID: 23263720 [Abstract] [Full Text] [Related]
16. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy. Jain S, Midha V, Sood A. Indian J Gastroenterol; 2011 Sep 03; 30(5):239-40. PubMed ID: 21986854 [No Abstract] [Full Text] [Related]
17. [Hepatitis C infection. Overweight virus carriers are more difficult to cure]. MMW Fortschr Med; 2004 Mar 25; 146(13):58. PubMed ID: 15219135 [No Abstract] [Full Text] [Related]
18. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses. Fabris P, Carlotto A, Del Bianco T, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Eur J Gastroenterol Hepatol; 2013 Dec 25; 25(12):1396-401. PubMed ID: 23743559 [Abstract] [Full Text] [Related]
19. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C. Dai CY, Huang CF, Chuang WL, Huang JF, Yu ML. Am J Gastroenterol; 2009 Sep 25; 104(9):2358-9. PubMed ID: 19727098 [No Abstract] [Full Text] [Related]
20. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV, ESSENTIAL II Study Group. Aliment Pharmacol Ther; 2015 Oct 25; 42(7):829-44. PubMed ID: 26238707 [Abstract] [Full Text] [Related] Page: [Next] [New Search]